Note: results can be filtered by year and/or keyword. To filter on year, select the appropriate year from the drop down menu. To filter on keyword, enter relevant term into open box, select appropriate keyword, and click "filter".
Statements, Speeches, Letters
-
MSF intervention on WHO reform at 66th World Health Assembly
WHO 66th World Health Assembly Agenda Item 11 - WHO ReformIntervention by Manica Balasegaram, Médecins Sans Frontières Thank you chair, The question of reform of WHO has been the subject of numerous discussions and papers since 2011.
Last updated 22 May 2013
www.msfaccess.org/content/msf-intervention-who-reform-66th-world-health-assembly -
Joint Letter to the 66th World Health Assembly: Follow-up of the report of the CEWG
On the opening of the 66th World Health Assembly, MSF along with other organisations and individuals, submitted a letter to the World Health Organization (WHO) and its Member States to "exercise leadership, ambition and innovative thinking in developing new paradigms to take forward the word of the Consultative Expert Working group on Research and Development (CEWG)". EXCERPT: "Distinguished Delegate,
Last updated 17 May 2013
www.msfaccess.org/content/joint-letter-66th-world-health-assembly-follow-report-cewg -
DNDi at ten: past success, future challenges
Since it was created in 2003, there is little doubt that the Drugs for Neglected Diseases initiative (DNDi) has been one of the most successful Product Development Partnerships (PDPs), with 6 new treatments delivered for 4 diseases in less than ten years. While these have been developed from existing or repurposed drugs, the achievement is tangible in that many of these treatments (like NECT, ASAQ fixed dose combination and SSG&PM) are being rolled out and scaled up in endemic countries where they are needed the most.
Last updated 16 May 2013
www.msfaccess.org/content/dndi-ten-past-success-future-challenges -
U.S. Penalises India for Promoting Access to Medicines Strategies by Placing it on Trade "Watch List"
The U.S. Trade Representative's decision to place India on its annual trade "Watch List" is a bully tactic being used to punish the country for taking steps to ensure access to affordable, lifesaving medicines and to prevent other developing countries from following similar strategies. By placing India on the Watch List in its annual Special 301 Report, the U.S. is disregarding the fact that India has acted within its rights under existing international trade rules and that its measures will increase access to medicines for millions.
Last updated 2 May 2013
www.msfaccess.org/content/us-penalises-india-promoting-access-medicines-strategies-placing-it-trade-watch-list -
MSF statement on GAVI's response to 'Dear GAVI' campaign
MSF launched the "Dear GAVI" campaign on 23 April to push for GAVI to extend its discounted prices on vaccines to MSF and other NGOs and humanitarian actors so that we can reach more of the most vulnerable children. In response, GAVI issued a statement and below is MSF's own response.
Last updated 24 April 2013
www.msfaccess.org/content/msf-statement-gavis-response-dear-gavi-campaign -
MSF responds to Decade of Vaccines supplement launch in the journal VACCINES
Last updated 18 April 2013
www.msfaccess.org/content/msf-responds-decade-vaccines-supplement-launch-journal-vaccines -
Letter from MSF to the Indian Prime Minister regarding access to medicines and the EU-India FTA
Geneva, 14 March 2013 Honourable Prime Minister Re: Access to medicines and the EU-India FTA
Last updated 18 March 2013
www.msfaccess.org/content/letter-msf-indian-prime-minister-regarding-access-medicines-and-eu-india-fta -
India upholds compulsory licence on cancer drug in Bayer case appeal
New Delhi/Geneva, 4 March 2013 – The verdict into German pharmaceutical company Bayer’s appeal against the grant of a compulsory licence has been issued by India’s Intellectual Property Appellate Board (IPAB) in Chennai. Médecins Sans Frontières (MSF) has learnt that the IPAB has upheld the first compulsory licence granted to a generic manufacturer issued in March 2012 for the kidney and liver cancer drug sorafenib tosylate.
Last updated 4 March 2013
www.msfaccess.org/content/india-upholds-compulsory-licence-cancer-drug-bayer-case-appeal -
MSF Intervention on Neglected Tropical Diseases at 132nd WHO Executive Board
Médecins Sans Frontières welcomes the renewed attention and focus on Neglected Tropical Diseases, and the ambitious goals in the WHO roadmap aimed at significantly reducing disease burden. MSF would urge member states to consider three aspects, where the roadmap and the Resolution could be improved, however:
Last updated 25 January 2013
www.msfaccess.org/content/msf-intervention-neglected-tropical-diseases-132nd-who-executive-board -
MSF Intervention on CEWG: Financing & Coordination at 132nd WHO Executive Board
MSF is deeply disappointed with both the report of the meeting of Member States on the CEWG report and the draft Resolution. Despite a clear restatement of the failures of the current R&D system to deliver affordable, accessible and appropriate medical tools to meet the needs of people in developing countries, Member States are being asked to pass - unopened - an extremely weak Resolution which threatens to change nothing.
Last updated 25 January 2013
www.msfaccess.org/content/msf-intervention-cewg-financing-coordination-132nd-who-executive-board
Pages
